FDA-approved Sexual & reproductive

Leuprolide

Leuprolide is a GnRH agonist. It is filed in this library under sexual & reproductive, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Leuprolide has an FDA-approved product on the U.S. market, marketed as Vabrinty under application NDA021379.

The current label is held by Uronova Pharmaceuticals, Inc.

From the FDA label

What Leuprolide is approved to treat

is indicated for the treatment of advanced prostate cancer.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Leuprolide, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on sexual & reproductive

Markers on this pathway

What is measured when the pituitary-gonadal axis is assessed

Leuprolide's FDA-approved label indicates it for a condition managed by suppressing or controlling gonadotropin release. These are the markers clinicians use when assessing the pituitary-gonadal axis. They are listed here so you can read about them, not as a statement that Leuprolide changes any of them.

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Leuprolide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides